A similar setup was tested in CT26 and C51 tumor models, applying an isoeffective radiation dose (5 Gy).20 Neither the addition of anti-CTLA-4, anti-PD-1 nor anti-PD-L1 to RT+L19–IL2 resulted in improved therapeutic outcomes for both models (figure 1C, D, table 1), which was confirmed in the C51 model in an independent experiment (online supplemental figure 2). Here, CTLA4 is linked to neoplasm.